använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.

Corporate Finance

Vator Securities provides an extensive range of capital markets and advisory services to cutting-edge public and private growth companies with an emphasis on the Life Sciences, Medical Technology and Diagnostics sectors.

read more

Equity Research

Commissioned research by Vator Securities is offered to selected life science companies – "By Invitation Only". Commissioned researches are published continuously.

read more

WCVB Channel 5 News aired a segement with 
Immunovias IMMray® PanCan-d for early detection of pancreatic cancer on May 2nd 2019. Click here to watch the video.

Vator Securities Sole Bookrunner in Nanoform SEK 106 million private placement

Nanoform, an innovative medicine enabling nanotechnology company, announced the completion of a private placement totaling €10 million, with Ilmarinen Mutual Pension Insurance Company and Mandatum Life Insurance Company (Sampo Group) acting as anchor investors.

read more

Vator Securities advises Empros Pharma on 40 MSEK private placement

Subscribers in the issue are both existing shareholders Thomas Eldered, Directors of the Board and Management as well as new shareholders with extensive investment experience from the Life Science sector. Thomas Eldered remains the main shareholder in the Company.

read more

Vator Securities advises Xbrane Biopharma on 238 MSEK Directed and Rights Issue

The subscribers in the Directed Share Issue are, amongst other, STADA Arzneimittel AG, NYIP (Nyenburgh Investment Partners), Swedbank Robur Medica, Belsize Asset Management GmbH and Serendipity Group AB.

read more

Xlucane Product Launch Insight with STADA and Xbrane Biopharma

Vator Securities hosted a Product Launch Insight event for Xlucane together with German STADA Arzneimittel and Xbrane Biopharma yesterday, 11 April 2019.

read more

More News